Table 1.
Compound | * R | * R′ | Affinities (nM)a | In Vivo ED50s (μmol/kg)** | Avg. Potency | |||
---|---|---|---|---|---|---|---|---|
CB1 | CB2 | SA | %MPE | RT | ||||
Δ9-THC | ----- | ----- | 41b (2) | 36c (10) | 0.9 d | 2.6 d | 2.6 d | 2.0 |
JWH-018 | Naphthoyl | H | 9d (5) | 3 (3) | 0.3d | ~ 0.09d | 1.8d | 0.7 |
JWH-167 | Phenyl | H | 90 (17) | 159 (14) | 1.6 (0.9–2.6) | 1.3 (0.7–2.3) | 13 (7–23) | 5.3 |
JWH-205 | Phenyl | CH3 | 134 (23) | 180 (9) | 19 (9–34) | 13 (9–19) | 13 (9–16) | 15 |
JWH-251 | 2-Methylphenyl | H | 29 (3) | 146 (36) | 0.9 (0.6–1.6) | 0.9 (0.6–1.3) | 6 (3–9) | 2.6 |
JWH-252 | 2-Methylphenyl | CH3 | 23 (3) | 19 (0.6) | NT | NT | NT | --- |
JWH-208 | 4-Methylphenyl | H | 179 (10) | 570 (127) | 2.8 (0.9–9) | 16 (9–25) | 38 (22–63) | 18.9 |
JWH-209 | 4-Methylphenyl | CH3 | 746 (49) | 1353 (270) | 39 (21–75) | 57 (33–99) | 81 (42–153) | 59 |
JWH-250 | 2-Methoxyphenyl | H | 11 (2) | 33 (3) | NT | NT | NT | --- |
JWH-306 | 2-Methoxyphenyl | CH3 | 25 (1) | 82 (11) | 87% (2.9 μg/kg) | 1.1 (0.9–1.4) | 1.1 (0.9–1.7) | 1.1 |
JWH-302 | 3-Methoxyphenyl | H | 17 (2) | 89 (15) | 0.6 (0.3–1.2) | 0.9 (0.6–1.2) | 3 (2.1–4.2) | 1.5 |
JWH-253 | 3-Methoxyphenyl | CH3 | 62 (10) | 33 (3) | NT | NT | NT | --- |
JWH-201 | 4-Methoxyphenyl | H | 1064 (21) | 444 (14) | 84% (90 μg/kg) | 35% (90 μg/kg) | −2.3 (90 μg/kg) | --- |
JWH-202 | 4-Methoxyphenyl | CH3 | 1678 (62) | 645 (6) | 26 (11–51) | 51 (29–97) | −2.5 (86 μg/kg) | 38.5 |
See Figure 1.
SA = spontaneous activity, %MPE = % maximum possible antinociceptive effect, RT = rectal temperature, NT = not tested. Values shown are ED50s (95% confidence intervals). Single dose tests are indicated by magnitude of effect and dose (in parentheses). Average potency was calculated as the average of all ED50 values for the compound.
(Huffman et al., 2005a) CB1 and CB2 affinities of all 1-pentyl-3-phenylacetylindoles presented first in this publication. Values shown are Ki (± SEM).